Autres langues Hyloris Pharmaceuticals SA

Actions

HYL

BE0974363955

Produits pharmaceutiques

Marché Fermé - Euronext Bruxelles Autres places de cotation 17:55:00 12/05/2026			Varia. 5j.	Varia. 1 janv.
5,360 ^EUR	+2,68%		+3,88%	-21,64%

26/03	Hyloris Pharmaceuticals SA publie ses résultats pour l'exercice clos le 31 décembre 2025	CI
20/01	Hyloris Pharmaceuticals s'associe à Orion pour la commercialisation d'un traitement contre l'acidité gastrique	MT

Autres langues

08/05	Hyloris Pharmaceuticals : Regulated Information Hyloris’ Annual General Shareholders Meeting on June 9, 2026 ENGLISH VERSION
08/05	Hyloris Pharmaceuticals : Regulated Information Hyloris’ Annual General Shareholders Meeting on June 9, 2026 FRENCH VERSION
30/04	Hyloris Pharmaceuticals : releases Annual Report 2025
30/04	Hyloris Pharmaceuticals : Regulated Information Hyloris releases Annual Report 2025 ENGLISH VERSION
29/03	Chemie voert Bel20 aan
26/03	Kepler Cheuvreux ziet nog geen kantelpunt bij Hyloris
26/03	Lagere omzet en stabiel verlies bij Hyloris
26/03	Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones
26/03	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025
22/02	Azelis en Umicore onderuit na cijfers
19/02	Hyloris loopt vertraging op bij FDA-goedkeuring
19/02	Hyloris loopt vertraging op bij FDA-goedkeuring
19/02	Hyloris Pharmaceuticals : Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension ENGLISH VERSION
19/02	Hyloris Pharmaceuticals : Provides Update on FDA Review of Valacyclovir for Oral Suspension
02/02	Hyloris Pharmaceuticals : Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings
20/01	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment
19/01	Hyloris vindt partner voor vermarkten van maagzuurbehandeling
19/01	Hyloris Pharmaceuticals : Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets
19/01	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets ENGLISH VERSION
31/12	Hyloris tekent licentie voor mogelijke behandeling voor de ziekte van Wilson
31/12	Hyloris Secures European, Turkish License for ArborMed's Rare Disease Drug
30/12	Hyloris Pharmaceuticals : Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed
30/12	Hyloris Pharmaceuticals obtains exclusive license rights in Europe & Turkey from Arbormed for its Wilson's disease therapy
30/12	Hyloris kondigt samenwerking aan met Rosemont Pharmaceuticals
30/12	Hyloris Pharmaceuticals, Rosemont Pharmaceuticals Sign US Licensing, Supply Deal for Atomoxetine Oral Solution